Amphastar board authorizes $50M increase to share buyback program to offset dilution

Amphastar Pharmaceuticals, Inc.

$50M increase to buyback program authorized June 3, 2024; program continues indefinitely.
Primary goal is to offset dilution from equity compensation programs.
Purchases may be via open market, block trades, Rule 10b5-1 plans, or negotiated transactions.
Timing and number of shares repurchased depend on price, corporate and regulatory factors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.